Filtered By:
Condition: Cholesterol
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 42422 results found since Jan 2013.
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.METHODS: This critical review evaluated how recent publications and ongoing clinical trials in atherosclerotic inflammation will affect clinical care.FINDINGS: Key trials, including CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) with canakinumab (interleukin-1β inhibition), and COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) with colchicine, have shown that suppressing inflammation can improve outcomes in ASCV...
Source: Clinical Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: N Mohammadnia T S J Opstal S El Messaoudi W A Bax J H Cornel Source Type: research
Emerging therapies in dyslipidaemias
Vascul Pharmacol. 2023 Sep 14:107229. doi: 10.1016/j.vph.2023.107229. Online ahead of print.ABSTRACTSeveral observations have shown that elevated levels of low-density lipoprotein cholesterol (LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for reducing cardiovascular risk, with a continuous linear correlation between LDL-C reduction and cardiovascular benefit. Based on these observations, current guidelines have further lowered LDL-C goals and call for the use of more effective therapeutic interventions. In addition to statins, ezetimibe and the monoclonal antibodies targeting PCSK9, several...
Source: Vascular Pharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Alberico L Catapano Source Type: research
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.METHODS: This critical review evaluated how recent publications and ongoing clinical trials in atherosclerotic inflammation will affect clinical care.FINDINGS: Key trials, including CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) with canakinumab (interleukin-1β inhibition), and COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) with colchicine, have shown that suppressing inflammation can improve outcomes in ASCV...
Source: Atherosclerosis - September 16, 2023 Category: Cardiology Authors: N Mohammadnia T S J Opstal S El Messaoudi W A Bax J H Cornel Source Type: research
Cholesterol homeostasis, mechanisms of molecular pathways, and cardiac health: a current outlook
Curr Probl Cardiol. 2023 Sep 14:102081. doi: 10.1016/j.cpcardiol.2023.102081. Online ahead of print.ABSTRACTThe metabolism of lipoproteins, which regulates the transit of the lipid to and from tissues, is crucial to maintaining cholesterol homeostasis. Cardiac remodeling is referred to as a set of molecular, cellular, and interstitial changes that, following injury, affect the size, shape, function, mass, and geometry of the heart. Acetyl coenzyme A (acetyl CoA), which can be made from glucose, amino acids, or fatty acids, is the precursor for the synthesis of cholesterol. In this article, authors explain concepts behind c...
Source: Atherosclerosis - September 16, 2023 Category: Cardiology Authors: Rajiv Kumar Neelam Chhillar Dhruv Sanjay Gupta Ginpreet Kaur Shailey Singhal Tanya Chauhan Source Type: research
Safety of antenatal predniso(lo)ne and dexamethasone on fetal, neonatal and childhood outcomes: a systematic review
CONCLUSIONS: Based on the limited evidence found in this systematic review, predniso(lo)ne may have less side-effects compared to dexamethasone in short- and long-term outcomes. Current literature shows minimal risk of side-effects in the newborn by administration of a prenatal predniso(lo)ne dose of up to 10 mg per day.PMID:37715964 | DOI:10.1210/clinem/dgad547
Source: The Journal of Clinical Endocrinology and Metabolism - September 16, 2023 Category: Endocrinology Authors: Elise M A Slob Jacqueline U M Termote Janna W Nijkamp Hetty J Van der Kamp Erica L T van den Akker Source Type: research
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.METHODS: This critical review evaluated how recent publications and ongoing clinical trials in atherosclerotic inflammation will affect clinical care.FINDINGS: Key trials, including CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) with canakinumab (interleukin-1β inhibition), and COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) with colchicine, have shown that suppressing inflammation can improve outcomes in ASCV...
Source: Atherosclerosis - September 16, 2023 Category: Cardiology Authors: N Mohammadnia T S J Opstal S El Messaoudi W A Bax J H Cornel Source Type: research
Cholesterol homeostasis, mechanisms of molecular pathways, and cardiac health: a current outlook
Curr Probl Cardiol. 2023 Sep 14:102081. doi: 10.1016/j.cpcardiol.2023.102081. Online ahead of print.ABSTRACTThe metabolism of lipoproteins, which regulates the transit of the lipid to and from tissues, is crucial to maintaining cholesterol homeostasis. Cardiac remodeling is referred to as a set of molecular, cellular, and interstitial changes that, following injury, affect the size, shape, function, mass, and geometry of the heart. Acetyl coenzyme A (acetyl CoA), which can be made from glucose, amino acids, or fatty acids, is the precursor for the synthesis of cholesterol. In this article, authors explain concepts behind c...
Source: Atherosclerosis - September 16, 2023 Category: Cardiology Authors: Rajiv Kumar Neelam Chhillar Dhruv Sanjay Gupta Ginpreet Kaur Shailey Singhal Tanya Chauhan Source Type: research
Emerging therapies in dyslipidaemias
Vascul Pharmacol. 2023 Sep 14:107229. doi: 10.1016/j.vph.2023.107229. Online ahead of print.ABSTRACTSeveral observations have shown that elevated levels of low-density lipoprotein cholesterol (LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for reducing cardiovascular risk, with a continuous linear correlation between LDL-C reduction and cardiovascular benefit. Based on these observations, current guidelines have further lowered LDL-C goals and call for the use of more effective therapeutic interventions. In addition to statins, ezetimibe and the monoclonal antibodies targeting PCSK9, several...
Source: Vascular Pharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Alberico L Catapano Source Type: research
Safety of antenatal predniso(lo)ne and dexamethasone on fetal, neonatal and childhood outcomes: a systematic review
CONCLUSIONS: Based on the limited evidence found in this systematic review, predniso(lo)ne may have less side-effects compared to dexamethasone in short- and long-term outcomes. Current literature shows minimal risk of side-effects in the newborn by administration of a prenatal predniso(lo)ne dose of up to 10 mg per day.PMID:37715964 | DOI:10.1210/clinem/dgad547
Source: The Journal of Clinical Endocrinology and Metabolism - September 16, 2023 Category: Endocrinology Authors: Elise M A Slob Jacqueline U M Termote Janna W Nijkamp Hetty J Van der Kamp Erica L T van den Akker Source Type: research
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.METHODS: This critical review evaluated how recent publications and ongoing clinical trials in atherosclerotic inflammation will affect clinical care.FINDINGS: Key trials, including CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) with canakinumab (interleukin-1β inhibition), and COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) with colchicine, have shown that suppressing inflammation can improve outcomes in ASCV...
Source: Clinical Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: N Mohammadnia T S J Opstal S El Messaoudi W A Bax J H Cornel Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
ANGPTL3 Deficiency and Risk of Hepatic Steatosis
CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in ANGPTL3, as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.PMID:37712257 | DOI:10.1161/CIRCULATIONAHA.123.065866
Source: Circulation - September 15, 2023 Category: Cardiology Authors: Laura D'Erasmo Michele Di Martino Thomas Neufeld Tyler J Fraum Chul Joo Kang Kendall H Burks Alessia Di Costanzo Ilenia Minicocci Simone Bini Marianna Maranghi Giovanni Pigna Giancarlo Labbadia Jie Zheng Davide Fierro Anna Montali Fabrizio Ceci Carlo Cata Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
2023 Chinese guideline for lipid management
Front Pharmacol. 2023 Aug 29;14:1190934. doi: 10.3389/fphar.2023.1190934. eCollection 2023.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of Chinese guideline for lipid management is imperative, especially since the target lipid levels in the general population vary in respe...
Source: Atherosclerosis - September 15, 2023 Category: Cardiology Authors: Jian-Jun Li Shui-Ping Zhao Dong Zhao Guo-Ping Lu Dao-Quan Peng Jing Liu Zhen-Yue Chen Yuan-Lin Guo Na-Qiong Wu Sheng-Kai Yan Zeng-Wu Wang Run-Lin Gao Source Type: research
